Company intelligence / Profile preview

Peptisyntha

Brussels, Belgiumpharmaceutical-business-review.com ↗

Ownership: Private
Development stage: Commercial

Overview

Peptisyntha was recognized for its expertise in custom process development and cGMP contract manufacturing of therapeutic peptides at all stages from preclinical through commercialization. It developed proprietary cost-effective peptide synthesis technologies and served global pharmaceutical, biotech, diagnostic, and cosmetic clients. The company was acquired by International Chemical Investors Group/CordenPharma in 2013; its Brussels site became part of the CordenPharma network[5].

Modalities: PeptidesPeptide-drug conjugate (if applicable)
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Peptisyntha.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptisyntha.

Explore the full profile